Evogene shares rise 10.53% premarket after subsidiary licenses microbiome cancer therapy BMC128 to Shanghai Lishan.

Evogene surged 10.53% in premarket trading following the announcement of an exclusive global licensing agreement between its subsidiary Biomica and Shanghai Lishan Biopharmaceuticals for BMC128, a microbiome-based therapeutic for renal and lung cancer. The deal grants Lishan Biotech rights to develop, manufacture, and commercialize BMC128, which is completing Phase 1 trials with promising safety and early efficacy data, including stabilization of disease progression in previously treated patients. Biomica is eligible for milestone payments and royalties, positioning Evogene to benefit from future development and commercialization milestones. The collaboration leverages Lishan Biotech’s clinical development expertise and Evogene’s microbiome innovation, signaling strategic value creation in oncology. The news directly aligns with the stock’s upward movement, as the partnership advances BMC128 toward Phase 2 trials and regulatory filings in key markets.